Literature DB >> 34268118

Comprehensive Roles and Future Perspectives of Exosomes in Peritoneal Metastasis of Gastric Cancer.

Xiangliu Chen1, Haiyong Wang1, Yingying Huang1, Yanyan Chen1, Chuanzhi Chen1, Wei Zhuo2, Lisong Teng1.   

Abstract

Gastric cancer (GC) is one of the most prevalent digestive malignancies. A great number of patients at first visit or post curative resections are diagnosed with widespread metastasis within the peritoneal cavity. Overwhelming evidence has demonstrated that exosomes, a variety of biologically functional extracellular vesicles comprising active factors, mediate the progression and metastasis of GC. Although the regulatory mechanisms of exosomes remain fairly elusive, they are responsible for intercellular communication between tumor cells and normal stroma, cancer-related fibroblasts, immune cells within the primary tumor and metastatic niche. In this review, we provide new insight into the molecular signatures of GC-associated exosomes in reprogramming the tumor microenvironment and the subsequent promotion of peritoneal metastasis-including infiltration of the gastric wall, implantation of tumor cells onto the pre-metastatic peritoneum, and remodeling of the pre-metastatic niche. Based on this review, we hope to draw a more general conclusion for the functions of exosomes in the progression and peritoneal metastasis of GC and highlight the future perspective on strategies targeting exosomes in prognostic biomarkers and therapy for peritoneal metastasis.
Copyright © 2021 Chen, Wang, Huang, Chen, Chen, Zhuo and Teng.

Entities:  

Keywords:  exosomes; gastric cancer; microenvironment; peritoneal metastasis; pre-metastatic niche

Year:  2021        PMID: 34268118      PMCID: PMC8276633          DOI: 10.3389/fonc.2021.684871

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  85 in total

Review 1.  Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials.

Authors:  Alexander V Vlassov; Susan Magdaleno; Robert Setterquist; Rick Conrad
Journal:  Biochim Biophys Acta       Date:  2012-04-01

2.  High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles.

Authors:  Andrea Longatti; Christina Schindler; Andie Collinson; Lesley Jenkinson; Carl Matthews; Laura Fitzpatrick; Margaret Blundy; Ralph Minter; Tristan Vaughan; Michael Shaw; Natalie Tigue
Journal:  Nanoscale       Date:  2018-07-16       Impact factor: 7.790

3.  Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis.

Authors:  Pilar Sandoval; Jose Antonio Jiménez-Heffernan; Ángela Rynne-Vidal; María Luisa Pérez-Lozano; Álvaro Gilsanz; Vicente Ruiz-Carpio; Raquel Reyes; Julio García-Bordas; Konstantinos Stamatakis; Javier Dotor; Pedro L Majano; Manuel Fresno; Carlos Cabañas; Manuel López-Cabrera
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

4.  Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors.

Authors:  Irene Thomassen; Yvette R van Gestel; Bert van Ramshorst; Misha D Luyer; Koop Bosscha; Simon W Nienhuijs; Valery E Lemmens; Ignace H de Hingh
Journal:  Int J Cancer       Date:  2013-08-05       Impact factor: 7.396

5.  Exosomal miR-106a derived from gastric cancer promotes peritoneal metastasis via direct regulation of Smad7.

Authors:  Meng Zhu; Ning Zhang; Shuixiang He; Xinlan Lu
Journal:  Cell Cycle       Date:  2020-04-08       Impact factor: 4.534

6.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.

Authors:  Atsushi Nashimoto; Kohei Akazawa; Yoh Isobe; Isao Miyashiro; Hitoshi Katai; Yasuhiro Kodera; Shunichi Tsujitani; Yasuyuki Seto; Hiroshi Furukawa; Ichiro Oda; Hiroyuki Ono; Satoshi Tanabe; Michio Kaminishi
Journal:  Gastric Cancer       Date:  2012-06-23       Impact factor: 7.370

7.  Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA.

Authors:  Haiyang Zhang; Yi Wang; Ming Bai; Junyi Wang; Kegan Zhu; Rui Liu; Shaohua Ge; JiaLu Li; Tao Ning; Ting Deng; Qian Fan; Hongli Li; Wu Sun; Guoguang Ying; Yi Ba
Journal:  Cancer Sci       Date:  2018-02-11       Impact factor: 6.716

8.  Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway.

Authors:  Jianmei Gu; Hui Qian; Li Shen; Xu Zhang; Wei Zhu; Ling Huang; Yongmin Yan; Fei Mao; Chonghui Zhao; Yunyan Shi; Wenrong Xu
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Authors:  Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Cell Biol       Date:  2008-11-16       Impact factor: 28.824

10.  Exosomes Carrying MicroRNA-155 Target Forkhead Box O3 of Endothelial Cells and Promote Angiogenesis in Gastric Cancer.

Authors:  Zhengyang Zhou; Haiyang Zhang; Ting Deng; Tao Ning; Rui Liu; Dongying Liu; Ming Bai; Guoguang Ying; Yi Ba
Journal:  Mol Ther Oncolytics       Date:  2019-10-31       Impact factor: 7.200

View more
  2 in total

Review 1.  Tumor vessel normalization and immunotherapy in gastric cancer.

Authors:  Xianzhe Yu; Shan He; Jian Shen; Qiushi Huang; Peng Yang; Lin Huang; Dan Pu; Li Wang; Lu Li; Jinghua Liu; Zelong Liu; Lingling Zhu
Journal:  Ther Adv Med Oncol       Date:  2022-07-18       Impact factor: 5.485

2.  Cuprous oxide-based nanocrystals with combined chemo/chemodynamic therapy to increase tumor drug sensitivity by reducing mitochondria-derived adenosine-triphosphate.

Authors:  Haoran He; Jiaming Wu; Min Liang; Yao Xiao; Xuejian Wei; Yuqin Cao; Zhiheng Chen; Tian Lin; Miaosheng Ye
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.